Endolymphatic sac tumor at the cerebellopontine angle: A case report and review of literature

Endolymphatic Sac Tumor. Post-Radiosurgery Evaluation Using Time-Resolved Imaging of Contrast Kinetics MR Angiography

Endolymphatic sac tumor (ELST) is a rare, aggressive hypervascular tumor of the posterior petrous bone. These tumors can manifest independently or in conjunction with Von Hippel-Lindau (VHL) syndrome. Currently, the primary treatment strategy involves complete surgical excision, though the role of radiotherapy remains debated.We are reporting a case of a 35-year-old female patient affected by ELST associated with VHL syndrome, managed solely through stereotactic radiosurgery and monitored by time-resolved imaging of contrast kinetics magnetic resonance sequence.

A Rare Case of Endolymphatic Sac Tumour: Clinical, Radiological, Pathological and Immunohistochemical Findings with Review of Literature

Endolymphatic sac tumour (ELST) is a rare low grade malignant epithelial tumour of the petrous temporal bone, thought to arise from papillary epithelium of the endolymphatic sac. They may occur sporadically or in association with Von-Hippel Lindau disease. ELST is extremely rare neoplasm with benign histopathological appearance and clinically destructive behaviour. Because of the rarity of this tumour, it can easily be confused with other tumours such as paraganglioma, middle ear adenoma, metastatic carcinomas or choroid plexus papilloma. We report here a rare case of ELST with review of literature and discuss the differentiating features of ELST from its mimickers, showing a papillary configuration.

Clinical response to pazopanib in a patient with endolymphatic sac tumor not associated with von Hippel-Lindau syndrome

Endolymphatic sac tumors (ELSTs) are rare, locally invasive, vascular tumors of the temporal bone. These lesions are associated with von Hippel-Lindau syndrome but may arise sporadically. Early surgical intervention is recommended to prevent permanent neurologic deficits; however, many ELSTs are unresectable or are subtotally resected due to neurovascular compromise. Chemotherapeutic salvage therapy in trials of neoplasms of associated syndromes has targeted angiogenesis with variable response. We present the case of a sporadic ELST, previously minimally responsive to bevacizumab, treated with pazopanib, a multi-kinase inhibitor and antiangiogenic, with good response. Cases such as our patient may demonstrate the utility of novel antiangiogenics in the treatment of these rare neoplasms, particularly when the tumor is unresectable or necessitates subtotal resection.